Braidwell LP Purchases 40,900 Shares of Vera Therapeutics, Inc. $VERA

Key Points

• Braidwell LP increased its Vera Therapeutics stake by 7.8%, purchasing 40,900 additional shares to reach 564,724 shares valued at approximately $24.2 million. Institutional investors collectively own 99.21% of the company.
• Vera shares were trading at $35.66, with a market capitalization of $2.57 billion, while the company reported a quarterly loss of $1.52 per share—better than analysts’ $1.58 estimate.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an $81.15 price target, although CEO Marshall Fordyce recently sold 46,250 shares for about $2.0 million under a prearranged trading plan.

Braidwell LP lifted its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 7.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 564,724 shares of the company's stock after buying an additional 40,900 shares during the period. Braidwell LP owned about 0.78% of Vera Therapeutics worth $24,232,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Los Angeles Capital Management LLC purchased a new position in shares of Vera Therapeutics during the fourth quarter worth approximately $46,000. Quantbot Technologies LP bought a new position in shares of Vera Therapeutics during the 2nd quarter valued at $51,000. Aster Capital Management DIFC Ltd bought a new position in shares of Vera Therapeutics during the 4th quarter valued at $71,000. Nykredit A S purchased a new position in Vera Therapeutics in the 2nd quarter worth $97,000. Finally, Tower Research Capital LLC TRC lifted its stake in Vera Therapeutics by 192.9% in the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company's stock worth $99,000 after purchasing an additional 2,757 shares during the last quarter. Institutional investors own 99.21% of the company's stock.

Vera Therapeutics Trading Up 4.2%

NASDAQ VERA opened at $35.66 on Thursday. The firm has a market capitalization of $2.57 billion, a PE ratio of -6.09 and a beta of 0.96. The stock's 50 day moving average is $36.10 and its 200 day moving average is $37.52. Vera Therapeutics, Inc. has a twelve month low of $21.71 and a twelve month high of $56.05. The company has a quick ratio of 10.92, a current ratio of 10.92 and a debt-to-equity ratio of 0.18.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings data on Monday, August 10th. The company reported ($1.52) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.58) by $0.06. During the same period in the prior year, the company posted ($1.20) earnings per share. Research analysts forecast that Vera Therapeutics, Inc. will post -6.43 earnings per share for the current fiscal year.

Analysts Set New Price Targets

VERA has been the topic of several analyst reports. Guggenheim lifted their price objective on Vera Therapeutics from $56.00 to $76.00 and gave the stock a "buy" rating in a report on Wednesday, July 8th. William Blair reaffirmed an "outperform" rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Evercore set a $91.00 price objective on Vera Therapeutics in a research report on Friday, May 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Vera Therapeutics in a report on Friday, July 17th. Finally, Needham & Company LLC set a $125.00 target price on shares of Vera Therapeutics in a research note on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Vera Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $81.15.

Insider Transactions at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 46,250 shares of the business's stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the sale, the chief executive officer owned 151,994 shares of the company's stock, valued at $6,429,346.20. The trade was a 23.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is currently owned by company insiders.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.

Want to see what other hedge funds are holding VERA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source